Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021058597 - METHODS OF DETERMINING WHETHER A SUBJECT IS AT RISK OF DEVELOPING ARTERIAL PLAQUES

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS:

1. A method of determining whether a subject is at risk of developing arterial plaques comprising determining the level of PCSK9 in a blood sample obtained from the subject wherein said level correlates with the risk of developing arterial plaque.

2. The method of claim 1 wherein the level of PCSK9 is compared to a predetermined reference value.

3. The method of claim 2 wherein when the level of PCSK9 is higher than the predetermined reference value, it is concluded that the patient is at risk of developing arterial plaques, or, when the level of PCSK9 is lower than the predetermined reference value, then is it concluded that the patient is not at risk of developing arterial plaques.

4. A method of determining whether a subject is at risk of developing arterial plaques comprising determining in a nucleic acid sample obtained from the subject the presence or absence of at least one genetic variant in the PCSK9 gene.

5. The method of claim 4 which comprises comprises detecting the rs562556 single nucleotide polymorphism.

6. The method of claim 5 wherein the presence of the minor allele “A” indicates that the subject is at risk of developing arterial plaques.

7. The method of claim 1 or 4 which further comprises measuring at least one other risk factor.

8. The method of claim 7 which comprises the use of an algorithm.

9. The method of claim 7 which comprises a) determining the level of PSCK9 in a blood sample obtained from the subject and/or detecting at least one genetic variant in the PCSK9 gene; b) implementing an algorithm on data comprising the level of PCSK9 and/or presence or absence of the genetic variant so as to obtain an algorithm output; c) determining the probability that the subject will develop arterial plaques.

10. The method of claim 1 or 4 which further comprises administering a PCSK9 antagonist or an inhibitor of PCSK9 expression when it is concluded that the patient is at risk of developing arterial plaques.